All Eyes on iSpecimen Inc. (Nasdaq: ISPC) Tomorrow Morning – See Why This is #1 on Our Watchlist for Early Thursday!

*Sponsored Market Crux Announces its Next Exclusive Profile…  All Eyes on iSpecimen Inc. (Nasdaq: ISPC) Tomorrow Morning – See Why This is #1 on Our Watchlist for Early Thursday! This under the radar company comes backed by several potential  catalysts including: Significant Revenue Growth: 76% year-over-year revenue increase in Q2 2024, fueled by Next Day Quotes and Supplier Refresh programs, highlighting growth potential. Earnings Report Anticipation: Expected release by November 19, drawing attention and putting iSpecimen Inc. (Nasdaq: ISPC) in the spotlight. Growing Market Demand: Positioned in the $3–$4B biospecimen market, growing at 10–15% annually, iSpecimen is set to meet rising demand for reliable sample access. Limited Float: With fewer than 544K  shares available, iSpecimen Inc. (Nasdaq: ISPC) could witness significant swings if demand starts to shift. November 6, 2024 Dear Reader, Coming off last Friday’s profile which made an approximate 39% move in under 24 hours, it’s time to turn your attention to our next potential breakout idea: iSpecimen Inc. (Nasdaq: ISPC). With its anticipated third-quarter earnings announcement on the horizon, iSpecimen Inc. (Nasdaq: ISPC) has the potential to draw attention as a prominent name in the biospecimen marketplace sector. A standout feature of iSpecimen Inc. (Nasdaq: ISPC) is its razor-thin float of fewer than 544k.  This low float could make iSpecimen Inc. (Nasdaq: ISPC) highly responsive to demand changes, which could lead to the potential for big swings.  With its recent market recognition, iSpecimen Inc. (Nasdaq: ISPC) moved approximately 60% in less than a week, from $3.41 on 10/30/2024 to $5.48 on 11/04—a testament to its potential for quick moves. iSpecimen Inc. (Nasdaq: ISPC) operates a unique platform connecting scientists in need of biological samples for innovative research with a global network of healthcare providers.  This distinctive business model and recent milestones have driven impressive growth, solidifying iSpecimen Inc. (Nasdaq: ISPC) as an emerging player in the biotechnology field. With the third-quarter earnings report expected any day now, several online sources have speculated on the date.  Here’s what is being reported: MarketWatch: Suggests today Nasdaq: November 7, 2024 (tomorrow) CNBC: Anticipates this Friday Benzinga: Points to November 19, 2024 With this broad range of dates, the earnings announcement could come at any moment. Considering iSpecimen Inc. (Nasdaq: ISPC)’s recent fiscal and operational strides, now may be the perfect time to add this innovative company to your watchlist. Solid Fiscal Performance in Q2 2024 In Q2 2024, iSpecimen reported a significant 76% revenue growth year-over-year, reaching approximately $2.86M , up from $1.63M in Q2 2023.  This growth reflects the impact of recent initiatives led by CEO Tracy Curley, such as the Next Day Quotes program and a Supplier Refresh program.  Together, these programs have boosted conversion rates and accelerated order fulfillment, directly supporting the company’s impressive revenue growth. Important Highlights from Q2 2024 include: Revenue growth of 76% year-over-year, driven by a 26% increase in specimen volume and a 39% increase in average selling price per specimen. Next Day Quotes conversion: Around 58% of quotes converted into purchase orders, showcasing the program’s effectiveness in meeting customer needs promptly. Cost efficiency strides: General and administrative expenses decreased by 40% year-over-year, signaling effective cost control and a focus on pro-fit-ability. With these improvements, iSpecimen Inc. (Nasdaq: ISPC) has demonstrated its ability to attract demand, streamline operations, and efficiently manage resources—all positive indicators for its trajectory in the biospecimen market. Executive Appointments Fueling Long-Term Expansion Beyond fiscal achievements, iSpecimen Inc. (Nasdaq: ISPC) has strengthened its leadership team.  A key addition in Q2 2024 was Brielan Smiechowski, who joined as Senior Vice President of Sales and Business Development.  With over 15 years of sales experience in life sciences, Smiechowski is expected to drive growth through a focus on key customer accounts and a structured business development approach.  Her expertise aligns well with the company's growth ambitions, potentially enhancing iSpecimen’s reach and revenue streams. Enhanced Efficiency with a Leaner Supplier Network A significant component of iSpecimen’s 2024 strategy has been the targeted refinement of its supplier network.  The company reduced its supplier base from 243 at the end of 2023 to 105 by Q2 2024, focusing on building a smaller, high-quality supplier network.  This approach allows iSpecimen Inc. (Nasdaq: ISPC) to offer faster, more reliable sample sourcing, meeting the needs of researchers with improved speed and quality.  This strategic shift demonstrates the company’s commitment to operational excellence and a streamlined marketplace experience for users. Life Sciences Fuel Increased Demand for Biospecimens As the demand for biospecimen sourcing continues to rise,  iSpecimen Inc. (Nasdaq: ISPC)’s platform meets a vital need for researchers seeking timely and reliable access to samples.  The company’s scalable model and innovative quoting system align well with the fast-paced requirements of the biotechnology sector, making it a valuable resource in this competitive field. Market Awaits Anticipated Earnings Release Several sources, including Nasdaq, MarketWatch, CNBC, and Benzinga, are buzzing about iSpecimen’s upcoming earnings announcement, with potential dates ranging from today to November 19, 2024. This anticipation around the earnings report could lead to increased visibility, which may draw further attention to the company’s recent progress. iSpecimen Inc. (Nasdaq: ISPC) has made strides in controlling its general and administrative costs, achieving a 40% decrease year-over-year in Q2. Paired with a ca-sh position of $2.15M, this disciplined approach to cost control reflects a strong commitment to financial management.  This focus on efficiency and resource allocation supports iSpecimen Inc. (Nasdaq: ISPC)’s  growth strategy, which may appeal to those observing trends in cost efficiency. Start your research on  iSpecimen Inc. (Nasdaq: ISPC)... iSpecimen Inc. (Nasdaq: ISPC)’s recent fiscal performance, strategic operational enhancements, and leadership additions mark it as one company to keep an eye on for those interested in the biotechnology sector. The company’s streamlined processes, improved cost efficiency, and revenue growth signal its ability to capture demand in a growing industry. With multiple sources hinting at an imminent earnings announcement, iSpecimen Inc. (Nasdaq: ISPC) could become a target of interest.  As the anticipated earnings report approaches, numerous factors seem to align in favor of iSpecimen Inc. (Nasdaq: ISPC). For anyone tracking growth in biotechnology companies, iSpecimen Inc. (Nasdaq: ISPC) might be worth a closer look. 7 reasons to consider adding iSpecimen Inc. (Nasdaq: ISPC) to the top of your watchlist tomorrow morning… 1. Limited Float: With fewer than 544K shares available, iSpecimen Inc. (Nasdaq: ISPC)’s low float could amplify responsiveness to demand shifts, potentially leading to noticeable price movements. 2. Significant Revenue Momentum: iSpecimen Inc. (Nasdaq: ISPC) reported a 76% year-over-year revenue increase in Q2 2024, driven by strategic initiatives like the Next Day Quotes and Supplier Refresh programs, highlighting its growth potential in the biospecimen market. 3. Anticipated Earnings Announcement: Anticipation around iSpecimen Inc. (Nasdaq: ISPC)’s upcoming earnings report, expected any time between now and November 19, could generate significant interest, putting the company in the spotlight. 4. Innovative Digital Marketplace: iSpecimen’s unique platform connects researchers with healthcare providers globally, addressing inefficiencies in biospecimen sourcing, much like how other platforms revolutionized their industries. 5. Strengthened Leadership for Growth: The addition of Brielan Smiechowski as Senior VP of Sales & Business Development brings over 15 years of life sciences expertise, supporting iSpecimen Inc. (Nasdaq: ISPC)’s expansion and growth strategies. 6. Operational Efficiency: iSpecimen Inc. (Nasdaq: ISPC)  reduced its supplier network from 243 to 105 in 2024, allowing it to offer faster and more reliable biospecimen sourcing, a strategic shift that enhances operational excellence. 7. Growing Market Demand for Biospecimens: Within the $3–$4B biospecimen market growing at 10–15% annually, iSpecimen Inc. (Nasdaq: ISPC) is positioning itself for the rising demand of reliable biospecimen access in research. With its low float of less than 544K shares and robust revenue growth, iSpecimen Inc. (Nasdaq: ISPC) stands out in the biospecimen marketplace. The company’s innovative digital platform is transforming how researchers access essential samples, meeting demand efficiently and reliably.  As it addresses the needs of a $3–$4B market, the anticipation of its upcoming earnings report could help shine a spotlight on iSpecimen Inc. (Nasdaq: ISPC). Consider starting your research on iSpecimen Inc. (Nasdaq: ISPC). iSpecimen Inc. (Nasdaq: ISPC) will be #1 on our watchlist tomorrow. We will be up early watching (ISPC) so please reach out to us with any questions you may have. Plan on hearing from me early tomorrow morning. Have a good night. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/ Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired by TD Media LLC for a period beginning on 11/06/2024 and ending on 11/07/2024 to publicly disseminate information about (ISPC:US) via digital communications. Under this agreement, Headline Media LLC has been paid ten thousand USD (“Funds”) to disseminate information about (ISPC:US) via digital communications. These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Headline Media or its members own shares of (ISPC:US). Please see important disclosure information here: https://marketcrux.com/disclosure/ispc/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice